BioRegenx, Inc. (BRGX)
OTCMKTS · Delayed Price · Currency is USD
0.0080
0.00 (0.00%)
Aug 31, 2026, 4:00 PM EST
BioRegenx Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.05 | 0.07 | 0.06 | 0.13 | 0 | 0.88 |
Cash & Short-Term Investments | 0.05 | 0.07 | 0.06 | 0.13 | 0 | 0.88 |
Cash Growth | -45.23% | 18.80% | -53.43% | 18450.59% | -99.92% | 48.76% |
Receivables | 0.02 | 0.04 | 0.01 | 0.1 | - | 0 |
Inventory | 0.09 | 0.11 | 0.11 | 0.22 | - | 0.65 |
Prepaid Expenses | 0.01 | 0.01 | 0.01 | 0.06 | - | 0.24 |
Other Current Assets | 0.03 | 0.03 | 0.12 | 0.14 | - | 0.11 |
Total Current Assets | 0.19 | 0.25 | 0.31 | 0.65 | 0 | 1.89 |
Property, Plant & Equipment | 0.15 | 0.16 | 0.2 | 0.01 | - | 0.02 |
Long-Term Investments | - | - | - | - | 0.02 | - |
Other Intangible Assets | - | - | - | 0.05 | 0.04 | - |
Other Long-Term Assets | - | - | - | 0.15 | - | 0.01 |
Total Assets | 0.34 | 0.41 | 0.51 | 0.87 | 0.06 | 1.92 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.96 | 0.97 | 0.65 | 0.46 | 0.02 | 0.61 |
Accrued Expenses | 0.99 | 1 | 0.88 | 0.64 | - | 1 |
Short-Term Debt | 1.03 | 1.03 | 1.03 | 0.96 | - | 1.32 |
Current Portion of Long-Term Debt | 0.95 | 1 | 0.88 | 0.38 | 0.05 | - |
Current Unearned Revenue | 0.06 | 0.06 | 0.2 | 0.35 | - | 0.07 |
Total Current Liabilities | 3.99 | 4.07 | 3.63 | 2.79 | 0.06 | 2.99 |
Long-Term Debt | 0.18 | 0.18 | 0.25 | 0.15 | 0.2 | 2.19 |
Other Long-Term Liabilities | 0.7 | 0.7 | - | - | - | - |
Total Liabilities | 4.87 | 4.95 | 3.89 | 2.94 | 0.26 | 5.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.97 | 0.97 | 1.23 | 0.77 | 0.27 | 0 |
Additional Paid-In Capital | 31.64 | 31.61 | 30.97 | 9.68 | 2.44 | 2.7 |
Retained Earnings | -37.14 | -37.12 | -35.57 | -12.52 | -2.92 | -5.96 |
Comprehensive Income & Other | - | - | 0 | -0 | - | - |
Total Common Equity | -4.53 | -4.54 | -3.38 | -2.07 | -0.21 | -3.26 |
Shareholders' Equity | -4.53 | -4.54 | -3.38 | -2.07 | -0.2 | -3.26 |
Total Liabilities & Equity | 0.34 | 0.41 | 0.51 | 0.87 | 0.06 | 1.92 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.17 | 2.21 | 2.16 | 1.49 | 0.24 | 3.51 |
Net Cash (Debt) | -2.12 | -2.15 | -2.11 | -1.36 | -0.24 | -2.62 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.07 |
Filing Date Shares Outstanding | 971.58 | 969.02 | 956.99 | 956.63 | 38.88 | 36.17 |
Total Common Shares Outstanding | 971.58 | 969.02 | 956.99 | 956.63 | 38.58 | 36.17 |
Working Capital | -3.8 | -3.82 | -3.33 | -2.13 | -0.06 | -1.11 |
Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.09 |
Tangible Book Value | -4.53 | -4.54 | -3.38 | -2.12 | -0.25 | -3.26 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.09 |